Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BENOIT C PINEAU

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1619173309
CMS profile
300169
Location
ST. AUGUSTINE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$24,515.06

148 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 148 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BENOIT C PINEAU

NPI 1619173309 · CMS profile ID 300169

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

ST. AUGUSTINE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 148 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1619173309?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BENOIT C PINEAU, NPI 1619173309, CMS profile ID 300169. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 148 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1619173309?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). BENOIT C PINEAU, NPI 1619173309, CMS profile ID 300169. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 148 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1619173309?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
BENOIT C PINEAU, NPI 1619173309, CMS profile ID 300169, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 148 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1619173309?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

148 matching records · $24,515.06 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 148 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 148.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Madrigal Pharmaceuticals $17.6707/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248299568 CMS
Phathom Pharmaceuticals, Inc. $14.5207/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1219262405 CMS
Takeda Pharmaceuticals U.S.A., Inc. $15.2807/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223821004 CMS
GENZYME CORPORATION $24.4807/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233708648 CMS
ABBVIE INC. $16.1307/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203625293 CMS
ABBVIE INC. $28.9307/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203625301 CMS
Janssen Biotech, Inc. $8.2807/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175247599 CMS
Janssen Biotech, Inc. $8.5407/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175247642 CMS
Regeneron Healthcare Solutions, Inc. $42.0007/01/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1213014308 CMS
QOL Medical, LLC $25.0406/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1185016748 CMS
Aimmune Therapeutics, Inc. $22.5106/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249686901 CMS
Madrigal Pharmaceuticals $18.8806/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248299566 CMS
PFIZER INC. $16.1106/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228927419 CMS
Lilly USA, LLC $24.0806/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186532995 CMS
Phathom Pharmaceuticals, Inc. $18.9306/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1219356428 CMS
Takeda Pharmaceuticals U.S.A., Inc. $15.6206/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223823052 CMS
ABBVIE INC. $12.0706/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203625288 CMS
Regeneron Healthcare Solutions, Inc. $14.9106/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1213014306 CMS
Janssen Biotech, Inc. $15.7206/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175247617 CMS
ABBVIE INC. $17.8906/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203625281 CMS
Regeneron Healthcare Solutions, Inc. $44.8006/06/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1213014304 CMS
Madrigal Pharmaceuticals $18.8806/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248299564 CMS
Lilly USA, LLC $19.8706/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186532993 CMS
QOL Medical, LLC $33.5206/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1185016678 CMS
Janssen Biotech, Inc. $14.2806/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175247557 CMS
ABBVIE INC. $4.0405/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203625275 CMS
Takeda Pharmaceuticals U.S.A., Inc. $22.4305/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223877610 CMS
GENZYME CORPORATION $22.2005/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233708792 CMS
Takeda Pharmaceuticals U.S.A., Inc. $16.1505/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223826554 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $23.4705/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231817728 CMS
Regeneron Healthcare Solutions, Inc. $5,577.0005/13/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1213014300 CMS
Regeneron Healthcare Solutions, Inc. $5,577.0005/13/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1213014302 CMS
ABBVIE INC. $17.0605/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203625270 CMS
Regeneron Healthcare Solutions, Inc. $57.4005/09/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1213014298 CMS
Regeneron Healthcare Solutions, Inc. $125.5705/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1213014296 CMS
Madrigal Pharmaceuticals $17.6305/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248299562 CMS
Janssen Biotech, Inc. $15.3104/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175247549 CMS
Takeda Pharmaceuticals U.S.A., Inc. $22.6804/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223879359 CMS
Regeneron Healthcare Solutions, Inc. $5,577.0004/22/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1213014294 CMS
Regeneron Healthcare Solutions, Inc. $127.5004/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1213014292 CMS
ABBVIE INC. $126.5404/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203625263 CMS
Lilly USA, LLC $19.7304/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186486897 CMS
Madrigal Pharmaceuticals $15.4504/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248299560 CMS
Janssen Biotech, Inc. $13.8704/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175247524 CMS
ABBVIE INC. $16.3304/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203625258 CMS
Lilly USA, LLC $18.7904/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186532991 CMS
GENZYME CORPORATION $19.2704/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233708780 CMS
Takeda Pharmaceuticals U.S.A., Inc. $17.6804/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223837990 CMS
Medtronic, Inc. $144.0004/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1218965726 CMS
Lilly USA, LLC $15.6503/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186525945 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,034.45 49
PY2020 $409.47 24
PY2021 $5,633.41 99
PY2022 $2,060.84 102
PY2023 $2,245.42 116
PY2024 $4,830.93 116
PY2025 $24,515.06 148

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $104,124.38 29
PY2024 Principal investigator $139,873.98 42
PY2023 Principal investigator $101,148.91 17
PY2022 Principal investigator $8,000.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

29 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $15,300.00 12/17/2025 Non-covered Recipient Entity
Jacksonville Center for Clinical Research
Study of DONQ52 in Active Celiac Disease No dispute reported 06/30/2026 1211617847
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $5,000.00 12/17/2025 Non-covered Recipient Entity
Jacksonville Center for Clinical Research
Study of DONQ52 in Active Celiac Disease No dispute reported 06/30/2026 1211617850
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $2,793.00 12/17/2025 Non-covered Recipient Entity
Jacksonville Center for Clinical Research
Study of DONQ52 in Active Celiac Disease No dispute reported 06/30/2026 1211617855
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $3,948.00 12/17/2025 Non-covered Recipient Entity
Jacksonville Center for Clinical Research
Study of DONQ52 in Active Celiac Disease No dispute reported 06/30/2026 1211617860
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $1,500.00 12/17/2025 Non-covered Recipient Entity
Jacksonville Center for Clinical Research
Study of DONQ52 in Active Celiac Disease No dispute reported 06/30/2026 1211617864
Principal investigator 1 Madrigal Pharmaceuticals $2,523.32 11/25/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248252845
Principal investigator 1 Madrigal Pharmaceuticals $2,189.74 10/16/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248251517
Principal investigator 1 Madrigal Pharmaceuticals $1,567.50 09/18/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248250221
Principal investigator 1 Madrigal Pharmaceuticals $500.00 09/04/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248249504
Principal investigator 1 Madrigal Pharmaceuticals $2,189.74 08/21/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248862
Principal investigator 1 Madrigal Pharmaceuticals $2,523.32 07/31/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248247730
Principal investigator 1 Madrigal Pharmaceuticals $11,475.00 07/31/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248247733
Principal investigator 1 Madrigal Pharmaceuticals $325.00 07/31/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248247737
Principal investigator 1 Madrigal Pharmaceuticals $10,665.00 07/10/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248246802
Principal investigator 1 Madrigal Pharmaceuticals $175.00 07/10/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248246806
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $15,597.50 07/09/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223282418
Principal investigator 1 Madrigal Pharmaceuticals $2,690.05 05/22/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248244396
Principal investigator 1 Madrigal Pharmaceuticals $1,507.50 05/22/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248244405
Principal investigator 1 Madrigal Pharmaceuticals $1,118.50 04/10/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248242287
Principal investigator 1 Madrigal Pharmaceuticals $622.50 04/10/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248242291
Principal investigator 1 Madrigal Pharmaceuticals $2,189.74 04/08/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248241926
Principal investigator 1 Madrigal Pharmaceuticals $810.00 03/13/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH LTD
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248240914
Principal investigator 1 Madrigal Pharmaceuticals $125.00 03/13/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH LTD
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248240918
Principal investigator 1 Madrigal Pharmaceuticals $5,010.60 03/06/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH LTD
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248240404
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $540.00 03/03/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223275791
Principal investigator 2 Madrigal Pharmaceuticals $1,800.00 02/13/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH LTD
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248239721
Principal investigator 1 Madrigal Pharmaceuticals $1,800.00 02/13/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH LTD
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248239725
Principal investigator 1 Madrigal Pharmaceuticals $5,213.37 02/06/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH LTD
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248239246
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,425.00 01/29/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEA
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Efficacy and Safety Study of Tezepelumab in Patients with Eosinophilic Esophagitis (CROSSING) No dispute reported 06/30/2026 1185547211